FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Klaus Borner

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Metabolic Clearance Rate

Anatomy

Feces

Co-author Network

Publications

TOP 3
Hend M Shubar; Sabrina Lachenmaier; Markus M Heimesaat; Uwe Lohman; Rachmat Mauludin; Rainer H Mueller; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Hend M Shubar; Ildiko R Dunay; Sabrina Lachenmaier; Margitta Dathe; Faris Nadiem Bushrab; Rachmat Mauludin; Rainer H Müller; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.
Olaf Burkhardt; Jolanta Majcher-Peszynska; Klaus Borner; Ralf G Mundkowski; Bernd Drewelow; Hartmut Derendorf; Tobias Welte
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Klaus Borner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Hend M Shubar; Sabrina Lachenmaier; Markus M Heimesaat; Uwe Lohman; Rachmat Mauludin; Rainer H Mueller; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Journal of drug targeting 2011;19(2):114-24.
2009: Hend M Shubar; Ildiko R Dunay; Sabrina Lachenmaier; Margitta Dathe; Faris Nadiem Bushrab; Rachmat Mauludin; Rainer H Müller; Rudolf Fitzner; Klaus Borner; Oliver Liesenfeld
The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.
Journal of drug targeting 2009;17(4):257-67.
2005: Olaf Burkhardt; Jolanta Majcher-Peszynska; Klaus Borner; Ralf G Mundkowski; Bernd Drewelow; Hartmut Derendorf; Tobias Welte
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
Journal of clinical pharmacology 2005;45(6):659-65.
2005: Olaf Burkhardt; Heino Stass; Uwe Thuss; Klaus Borner; Tobias Welte
Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.
Clinical pharmacokinetics 2005;44(9):969-76.
2003: Annette Lubasch; SU Ziege; B Brodersen; Klaus Borner; Peter Koeppe; Hartmut Lode
Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):670-7.
2002: Olaf Burkhardt; Klaus Borner; Nicolas von der Höh; Peter Köppe; Mathias Pletz; Carl Erik Nord; Hartmut Lode
Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers.
The Journal of antimicrobial chemotherapy 2002;50(5):707-12.
2002: Dagmar Mainz; Klaus Borner; Peter Koeppe; Jochen Kotwas; Hartmut Lode
Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
The Journal of antimicrobial chemotherapy 2002;50(5):699-706.
2002: Olaf Burkhardt; Klaus Borner; Heino Stass; Gabriele Beyer; Markus Allewelt; Carl Erik Nord; Hartmut Lode
Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Scandinavian journal of infectious diseases 2002;34(12):898-903.
2001: C Jung; E Engelmann; Klaus Borner; Gerd Offermann
Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.
Transplantation proceedings 2001;33(7-8):3621-3.
2001: Klaus Borner; E Borner; Hartmut Lode
Determination of linezolid in human serum and urine by high-performance liquid chromatography.
International journal of antimicrobial agents 2001;18(3):253-8.
2001: Hartmut Lode; N Von der Höh; SU Ziege; Klaus Borner; Carl Erik Nord
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora.
Scandinavian journal of infectious diseases 2001;33(12):899-903.
2000: Annette Lubasch; I Keller; Klaus Borner; Peter Koeppe; Hartmut Lode
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.
Antimicrobial agents and chemotherapy 2000;44(10):2600-3.
2000: K Peters; S Leitzke; J E Diederichs; Klaus Borner; Helmut Hahn; Rainer H Müller; S Ehlers
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
The Journal of antimicrobial chemotherapy 2000;45(1):77-83.
1999: Klaus Borner; H Hartwig; Hartmut Lode
Determination of trovafloxacin in human body fluids by high-performance liquid chromatography.
Journal of chromatography. A 1999;846(1-2):175-80.
1999: Klaus Borner; H Hartwig; S Leitzke; Helmut Hahn; Rainer H Müller; S Ehlers
HPLC determination of clofazimine in tissues and serum of mice after intravenous administration of nanocrystalline or liposomal formulations.
International journal of antimicrobial agents 1999;11(1):75-9.
1998: Hartmut Lode; Klaus Borner; Peter Koeppe
Pharmacodynamics of fluoroquinolones.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(1):33-9.
1998: Ralf Stahlmann; U Zippel; Charlotte Förster; Rudolf Schwabe; Mehdi Shakibaei; Hans-Joachim Merker; Klaus Borner
Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats.
Antimicrobial agents and chemotherapy 1998;42(6):1470-5.
1998: S Leitzke; W Bucke; Klaus Borner; R Müller; Helmut Hahn; S Ehlers
Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.
Antimicrobial agents and chemotherapy 1998;42(2):459-61.
1998: W E Bucke; S Leitzke; J E Diederichs; Klaus Borner; Helmut Hahn; S Ehlers; Rainer H Müller
Surface-modified amikacin-liposomes: organ distribution and interaction with plasma proteins.
Journal of drug targeting 1998;5(2):99-108.
1997: J A Zix; HF Geerdes-Fenge; M Rau; J Vöckler; Klaus Borner; Peter Koeppe; Hartmut Lode
Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
Antimicrobial agents and chemotherapy 1997;41(8):1668-72.
1997: P Schüler; K Zemper; Klaus Borner; Peter Koeppe; T Schaberg; Hartmut Lode
Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1997;10(5):1130-6.
1997: HF Geerdes-Fenge; B Goetschi; M Rau; Klaus Borner; Peter Koeppe; K Wettich; Hartmut Lode
Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva.
European journal of clinical pharmacology 1997;53(2):127-33.
1994: M Ritz; Hartmut Lode; M Fassbender; Klaus Borner; Peter Koeppe; C E Nord
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
Antimicrobial agents and chemotherapy 1994;38(3):455-9.
1994: Hartmut Lode; M Fassbender; T Schaberg; Klaus Borner; Peter Koeppe
Comparative pharmacokinetics of the new oral cephalosporins.
Drugs 1994;47 Suppl 3():10-9; discussion 19-20.
1993: Klaus Borner; E Borner; Hartmut Lode
Determination of a new cephalosporin, SCE-2787, in serum and urine by high-performance liquid chromatography.
Journal of chromatography 1993;615(1):174-9.
1993: M Fassbender; Hartmut Lode; T Schaberg; Klaus Borner; Peter Koeppe
Pharmacokinetics of new oral cephalosporins, including a new carbacephem.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(5):646-53.
1993: A Meissner; Klaus Borner
[Concentration of ciprofloxacin in bone tissue].
Aktuelle Traumatologie 1993;23(2):80-4.
1992: Klaus Borner; E Borner; Hartmut Lode
Determination of sparfloxacin in serum and urine by high-performance liquid chromatography.
Journal of chromatography 1992;579(2):285-9.
1992: K Bächer; M Schaeffer; Hartmut Lode; C E Nord; Klaus Borner; Peter Koeppe
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers.
The Journal of antimicrobial chemotherapy 1992;30(3):365-75.
1992: Hartmut Lode; C Müller; Klaus Borner; C E Nord; Peter Koeppe
Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.
Antimicrobial agents and chemotherapy 1992;36(1):144-9.
1992: D Kampf; Klaus Borner; A Pustelnik
Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.
European journal of clinical pharmacology 1992;42(1):95-9.
1991: D Kampf; Klaus Borner; H Hain; W Conrad
Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 1991;11(4):317-21.
1990: D Kampf; Klaus Borner; A Pustelnik
Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis.
The Journal of antimicrobial chemotherapy 1990;26 Suppl D():61-8.
1990: Hartmut Lode; G Höffken; M Boeckk; N Deppermann; Klaus Borner; Peter Koeppe
Quinolone pharmacokinetics and metabolism.
The Journal of antimicrobial chemotherapy 1990;26 Suppl B():41-9.
1990: A Saathoff; Hartmut Lode; B Hampel; K M Deppermann; Klaus Borner; Peter Koeppe
Pharmacokinetics of FCE 22891, a new oral penem.
Antimicrobial agents and chemotherapy 1990;34(6):1001-6.
1990: Hartmut Lode; E Wiley; P Olschewski; H Sievers; M Wintermantel; R Baetz; K Lebahn; M Reinke; J Wagner; Klaus Borner
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Scandinavian journal of infectious diseases. Supplementum 1990;68():50-5.
1990: Hartmut Lode; M Boeckh; G Höffken; M Kühn; H Gaffal; Klaus Borner; Peter Koeppe
Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function.
Scandinavian journal of infectious diseases. Supplementum 1990;72():9-13.
1989: K M Deppermann; M Boeckh; S Grineisen; F Shokry; Klaus Borner; Peter Koeppe; C Krasemann; J Wagner; Hartmut Lode
Combination effects of ciprofloxacin, clindamycin, and metronidazole intravenously in volunteers.
The American journal of medicine 1989;87(5A):46S-48S.
1989: Hartmut Lode; G Hoffken; Klaus Borner; Peter Koeppe
Ciprofloxacin intravenous dose variance.
The American journal of medicine 1989;87(5A):40S-45S.
1989: Klaus Borner; F Hahn; Peter Koeppe
Concentrations of vancomycin in human bone.
Journal of chemotherapy (Florence, Italy) 1989;1(4 Suppl):588-9.
1989: Arya Sharma; F Keller; M Boeckh; J Heitz; Klaus Borner
Quinine dosage in severe malaria with renal failure necessitating haemodialysis.
European journal of clinical pharmacology 1989;36(5):535-6.
1988: Hartmut Lode; G Höffken; P Olschewski; B Sievers; A Kirch; Klaus Borner; Peter Koeppe
Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
The Journal of antimicrobial chemotherapy 1988;22 Suppl C():73-9.
1988: F Hahn; Klaus Borner; Peter Koeppe
[Concentration of metronidazole in bones].
Aktuelle Traumatologie 1988;18(2):84-6.
1988: M Boeckh; Hartmut Lode; Klaus Borner; G Höffken; J Wagner; Peter Koeppe
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.
Antimicrobial agents and chemotherapy 1988;32(1):92-5.
1987: Hartmut Lode; R Wiley; G Höffken; J Wagner; Klaus Borner
Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections.
Antimicrobial agents and chemotherapy 1987;31(10):1491-6.
1987: Hartmut Lode; G Höffken; P Olschewski; B Sievers; A Kirch; Klaus Borner; Peter Koeppe
Pharmacokinetics of ofloxacin after parenteral and oral administration.
Antimicrobial agents and chemotherapy 1987;31(9):1338-42.
1987: D Kampf; Klaus Borner; S Huber
Metronidazole kinetics and liver function in hepatic cirrhosis.
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy 1987;6(2 Suppl):311-2.
1987: Hartmut Lode; G Höffken; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reimnitz; Klaus Borner; Peter Koeppe
Comparative pharmacokinetics of new quinolones.
Drugs 1987;34 Suppl 1():21-5.
1986: Klaus Borner; G Höffken; Hartmut Lode; Peter Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.
European journal of clinical microbiology 1986;5(2):179-86.
1985: G Höffken; Klaus Borner; P D Glatzel; Peter Koeppe; Hartmut Lode
Reduced enteral absorption of ciprofloxacin in the presence of antacids.
European journal of clinical microbiology 1985;4(3):345.
1985: G Höffken; Hartmut Lode; C Prinzing; Klaus Borner; Peter Koeppe
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
Antimicrobial agents and chemotherapy 1985;27(3):375-9.
1985: Klaus Borner; Hartmut Lode; B Hampel; M Pfeuffer; Peter Koeppe
Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration.
Chemotherapy 1985;31(4):237-45.
1984: D Kampf; Klaus Borner; M Möller; M Kessel
Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
Clinical pharmacology and therapeutics 1984;35(2):214-20.
1983: Klaus Borner; E Borner; Hartmut Lode; A Peters
Determination of cefmenoxime in human body fluids by high-performance liquid chromatography.
European journal of clinical microbiology 1983;2(1):17-21.